Do analysts prefer PSNL or STVN?

Personalis currently has a consensus target price of $14.54, indicating a potential downside of 8.58%. Given Personalis' higher possible upside, equities analysts clearly believe Personalis is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Personalis 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18 Stevanato Group 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.75

Which has better valuation & earnings, PSNL or STVN?

Stevanato Group has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Personalis $69.67M 23.90 -$81.27M -$1.09 N/A Stevanato Group €1.34B 4.34 €158.21M €0.56 34.31

Which has higher valuation and earnings, PSNL or SHC?

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Personalis $69.67M 23.90 -$81.27M -$1.09 N/A Sotera Health $1.16B 4.35 $77.94M $0.57 31.11

Is PSNL or SHC more profitable?

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Personalis -153.84% -46.47% -35.30% Sotera Health 13.44% 40.12% 7.55%

Which has stronger earnings and valuation, FTRE or PSNL?

Personalis has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.68B 0.80 -$986.20M -$0.91 N/A Personalis $69.67M 23.88 -$81.27M -$1.09 N/A

Is FTRE or PSNL more profitable?

Fortrea has a net margin of -3.18% compared to Personalis' net margin of -153.84%. Fortrea's return on equity of 10.72% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Personalis -153.84% -46.47% -35.30%

Personalis (PSNL) Competitors

$15.93 +0.03 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$15.81 -0.12 (-0.75%)

As of 07:45 PM Eastern

Compare

PSNL vs. STVN, SHC, ADPT, FTRE, and MRVI

Should you buy Personalis stock or one of its competitors? Personalis's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Fortrea (FTRE), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Personalis compare to Stevanato Group?

Personalis (NASDAQ:PSNL) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Personalis currently has a consensus target price of $14.54, indicating a potential downside of 8.58%. Given Personalis' higher possible upside, equities analysts clearly believe Personalis is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Stevanato Group	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75

In the previous week, Stevanato Group had 2 more articles in the media than Personalis. MarketBeat recorded 3 mentions for Stevanato Group and 1 mentions for Personalis. Personalis' average media sentiment score of 1.28 beat Stevanato Group's score of 0.75 indicating that Personalis is being referred to more favorably in the media.

Company	Overall Sentiment
Personalis	Positive
Stevanato Group	Positive

Personalis has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Stevanato Group has a net margin of 10.99% compared to Personalis' net margin of -153.84%. Stevanato Group's return on equity of 10.43% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Stevanato Group	10.99%	10.43%	6.16%

Stevanato Group has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	23.90	-$81.27M	-$1.09	N/A
Stevanato Group	€1.34B	4.34	€158.21M	€0.56	34.31

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Stevanato Group beats Personalis on 10 of the 17 factors compared between the two stocks.

How does Personalis compare to Sotera Health?

Personalis (NASDAQ:PSNL) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Personalis has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Sotera Health	13.44%	40.12%	7.55%

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	23.90	-$81.27M	-$1.09	N/A
Sotera Health	$1.16B	4.35	$77.94M	$0.57	31.11

61.9% of Personalis shares are held by institutional investors. Comparatively, 91.0% of Sotera Health shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 15.4% of Sotera Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Sotera Health had 7 more articles in the media than Personalis. MarketBeat recorded 8 mentions for Sotera Health and 1 mentions for Personalis. Personalis' average media sentiment score of 1.28 beat Sotera Health's score of 0.34 indicating that Personalis is being referred to more favorably in the media.

Company	Overall Sentiment
Personalis	Positive
Sotera Health	Neutral

Personalis presently has a consensus target price of $14.54, indicating a potential downside of 8.58%. Sotera Health has a consensus target price of $21.38, indicating a potential upside of 20.56%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts clearly believe Sotera Health is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Sotera Health	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Sotera Health beats Personalis on 13 of the 16 factors compared between the two stocks.

How does Personalis compare to Adaptive Biotechnologies?

Personalis (NASDAQ:PSNL) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

61.9% of Personalis shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Adaptive Biotechnologies had 11 more articles in the media than Personalis. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 1 mentions for Personalis. Personalis' average media sentiment score of 1.28 beat Adaptive Biotechnologies' score of 0.54 indicating that Personalis is being referred to more favorably in the media.

Company	Overall Sentiment
Personalis	Positive
Adaptive Biotechnologies	Positive

Adaptive Biotechnologies has higher revenue and earnings than Personalis. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	23.90	-$81.27M	-$1.09	N/A
Adaptive Biotechnologies	$308.08M	13.27	-$59.50M	-$0.41	N/A

Personalis currently has a consensus target price of $14.54, suggesting a potential downside of 8.58%. Adaptive Biotechnologies has a consensus target price of $30.06, suggesting a potential upside of 17.34%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Personalis has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Adaptive Biotechnologies has a net margin of -20.73% compared to Personalis' net margin of -153.84%. Adaptive Biotechnologies' return on equity of -36.81% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Summary

Adaptive Biotechnologies beats Personalis on 12 of the 16 factors compared between the two stocks.

How does Personalis compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Personalis has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.80	-$986.20M	-$0.91	N/A
Personalis	$69.67M	23.88	-$81.27M	-$1.09	N/A

Fortrea currently has a consensus price target of $22.60, suggesting a potential upside of 0.16%. Personalis has a consensus price target of $14.54, suggesting a potential downside of 8.52%. Given Fortrea's stronger consensus rating and higher possible upside, analysts clearly believe Fortrea is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	2 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.42
Personalis	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

61.9% of Personalis shares are owned by institutional investors. 0.7% of Fortrea shares are owned by insiders. Comparatively, 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fortrea has a net margin of -3.18% compared to Personalis' net margin of -153.84%. Fortrea's return on equity of 10.72% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Personalis	-153.84%	-46.47%	-35.30%

In the previous week, Fortrea had 5 more articles in the media than Personalis. MarketBeat recorded 6 mentions for Fortrea and 1 mentions for Personalis. Personalis' average media sentiment score of 1.28 beat Fortrea's score of 0.37 indicating that Personalis is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortrea	Neutral
Personalis	Positive

Fortrea has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Personalis has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market.

Summary

Fortrea beats Personalis on 9 of the 16 factors compared between the two stocks.

How does Personalis compare to Maravai LifeSciences?

Personalis (NASDAQ:PSNL) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Personalis presently has a consensus price target of $14.54, indicating a potential downside of 8.58%. Maravai LifeSciences has a consensus price target of $7.38, indicating a potential upside of 12.60%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Maravai LifeSciences had 2 more articles in the media than Personalis. MarketBeat recorded 3 mentions for Maravai LifeSciences and 1 mentions for Personalis. Personalis' average media sentiment score of 1.28 beat Maravai LifeSciences' score of 0.60 indicating that Personalis is being referred to more favorably in the media.

Company	Overall Sentiment
Personalis	Positive
Maravai LifeSciences	Positive

61.9% of Personalis shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Personalis has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Maravai LifeSciences has a net margin of -37.07% compared to Personalis' net margin of -153.84%. Maravai LifeSciences' return on equity of -15.70% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Personalis has higher earnings, but lower revenue than Maravai LifeSciences. Personalis is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	23.90	-$81.27M	-$1.09	N/A
Maravai LifeSciences	$185.74M	9.16	-$130.77M	-$0.52	N/A

Summary

Maravai LifeSciences beats Personalis on 10 of the 17 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSNL vs. The Competition

Export

Metric	Personalis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.67B	$10.91B	$7.42B	$12.93B
Dividend Yield	N/A	1.45%	2.52%	19.59%
P/E Ratio	N/A	32.47	274.96	25.38
Price / Sales	23.95	486.03	609.32	90.34
Price / Cash	N/A	27.31	76.68	52.75
Price / Book	5.42	6.11	10.32	6.02
Net Income	-$81.27M	$56.67B	$3.49B	$380.68M
7 Day Performance	-0.81%	-0.39%	-2.54%	-3.01%
1 Month Performance	-1.06%	5.00%	-6.87%	-5.59%
1 Year Performance	86.75%	23.15%	1.81%	-5.23%

Personalis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSNL Personalis	1.3939 of 5 stars	$15.93 +0.2%	$14.54 -8.8%	+93.4%	$1.67B	$69.65M	N/A	260	Positive News
STVN Stevanato Group	3.5075 of 5 stars	€19.41 +0.9%	N/A	-20.6%	€5.88B	€1.23B	34.66	6,010
SHC Sotera Health	3.7582 of 5 stars	$18.15 +0.5%	$21.50 +18.5%	+10.9%	$5.15B	$1.16B	31.84	3,000	News Coverage Analyst Forecast
ADPT Adaptive Biotechnologies	3.2454 of 5 stars	$25.57 -3.5%	$29.56 +15.6%	+64.4%	$4.23B	$276.98M	N/A	624	Analyst Forecast Insider Trade
FTRE Fortrea	2.2693 of 5 stars	$21.00 +0.8%	$22.10 +5.2%	+123.5%	$1.98B	$2.72B	N/A	14,300	Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalis (PSNL) Competitors

PSNL vs. STVN, SHC, ADPT, FTRE, and MRVI

How does Personalis compare to Stevanato Group?

Summary

How does Personalis compare to Sotera Health?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Summary

How does Personalis compare to Fortrea?

Summary

How does Personalis compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Personalis (PSNL) Competitors

PSNL vs. STVN, SHC, ADPT, FTRE, and MRVI

How does Personalis compare to Stevanato Group?

Do analysts prefer PSNL or STVN?

Does the media refer more to PSNL or STVN?

Which has more volatility and risk, PSNL or STVN?

Is PSNL or STVN more profitable?

Which has better valuation & earnings, PSNL or STVN?

Do institutionals & insiders have more ownership in PSNL or STVN?

Summary

How does Personalis compare to Sotera Health?

Which has more risk & volatility, PSNL or SHC?

Is PSNL or SHC more profitable?

Which has higher valuation and earnings, PSNL or SHC?

Do institutionals and insiders have more ownership in PSNL or SHC?

Does the media refer more to PSNL or SHC?

Do analysts rate PSNL or SHC?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Do institutionals & insiders have more ownership in PSNL or ADPT?

Does the media refer more to PSNL or ADPT?

Which has better earnings & valuation, PSNL or ADPT?

Do analysts rate PSNL or ADPT?

Which has more risk and volatility, PSNL or ADPT?

Is PSNL or ADPT more profitable?

Summary

How does Personalis compare to Fortrea?

Which has stronger earnings and valuation, FTRE or PSNL?

Do analysts rate FTRE or PSNL?

Do institutionals and insiders have more ownership in FTRE or PSNL?

Is FTRE or PSNL more profitable?

Does the media prefer FTRE or PSNL?

Which has more risk and volatility, FTRE or PSNL?

Summary

How does Personalis compare to Maravai LifeSciences?

Do analysts prefer PSNL or MRVI?

Does the media prefer PSNL or MRVI?

Do insiders & institutionals believe in PSNL or MRVI?

Which has more volatility & risk, PSNL or MRVI?

Is PSNL or MRVI more profitable?

Which has higher earnings & valuation, PSNL or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools